Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash from Financing Activities (2019 - 2025)

Cyclerion Therapeutics has reported Cash from Financing Activities over the past 5 years, most recently at $1.8 million for Q3 2025.

  • Quarterly results put Cash from Financing Activities at $1.8 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $3.1 million (changed N/A YoY), and the annual figure for FY2023 was $5.0 million, up 17224.14%.
  • Cash from Financing Activities for Q3 2025 was $1.8 million at Cyclerion Therapeutics, up from -$130000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for CYCN hit a ceiling of $30.6 million in Q2 2021 and a floor of -$130000.0 in Q2 2025.
  • Median Cash from Financing Activities over the past 3 years was $43000.0 (2021), compared with a mean of $3.8 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 2600.0% in 2021 and later plummeted 99.94% in 2022.
  • Cyclerion Therapeutics' Cash from Financing Activities stood at $85000.0 in 2021, then crashed by 85.88% to $12000.0 in 2022, then skyrocketed by 15116.67% to $1.8 million in 2025.
  • The last three reported values for Cash from Financing Activities were $1.8 million (Q3 2025), -$130000.0 (Q2 2025), and $1.4 million (Q1 2025) per Business Quant data.